BR9706897A - Composições antifúngicas com biodisponibilidade aperfeiçoada. - Google Patents

Composições antifúngicas com biodisponibilidade aperfeiçoada.

Info

Publication number
BR9706897A
BR9706897A BR9706897-7A BR9706897A BR9706897A BR 9706897 A BR9706897 A BR 9706897A BR 9706897 A BR9706897 A BR 9706897A BR 9706897 A BR9706897 A BR 9706897A
Authority
BR
Brazil
Prior art keywords
improved bioavailability
day
compositions
antifungal compositions
mixture
Prior art date
Application number
BR9706897-7A
Other languages
English (en)
Other versions
BR9706897B1 (pt
Inventor
Geert Verreck
Dany Thone
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26142825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9706897(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR9706897A publication Critical patent/BR9706897A/pt
Publication of BR9706897B1 publication Critical patent/BR9706897B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçõES ANTIFúNGICAS COM BIODISPONIBILIDADE APERFEIçOADA"<D>. A presente invenção refere-se a novas composições farmacêuticas de itraconazol, as quais podem ser administradas a um mamífero que sofre de uma infecção fúngica, pela qual uma forma de dosagem única pode ser administrada uma vez ao dia e, além disso, a qualquer momento do dia, independentemente do alimento ingerido pelo referido mamífero. Essas novas composições compreendem partículas obteníveis por meio de extrusão por fusão de uma mistura compreendendo itroconazol e um polímero solúvel em água adequado e, subseq³entemente, trituração da referida mistura extrudada por fusão.
BRPI9706897-7A 1996-05-20 1997-05-12 forma de dosagem farmacêutica. BR9706897B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96201430 1996-05-20
EP97200698 1997-03-07
PCT/EP1997/002507 WO1997044014A1 (en) 1996-05-20 1997-05-12 Antifungal compositions with improved bioavailability

Publications (2)

Publication Number Publication Date
BR9706897A true BR9706897A (pt) 1999-08-31
BR9706897B1 BR9706897B1 (pt) 2010-09-21

Family

ID=26142825

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9706897-7A BR9706897B1 (pt) 1996-05-20 1997-05-12 forma de dosagem farmacêutica.

Country Status (34)

Country Link
US (4) US6509038B2 (pt)
EP (1) EP0904060B1 (pt)
JP (1) JP3391801B2 (pt)
KR (1) KR19990044257A (pt)
CN (1) CN1165291C (pt)
AR (1) AR007195A1 (pt)
AT (1) ATE255883T1 (pt)
AU (1) AU722101B2 (pt)
BG (1) BG64368B1 (pt)
BR (1) BR9706897B1 (pt)
CA (1) CA2240161C (pt)
CY (1) CY2434B1 (pt)
CZ (1) CZ293841B6 (pt)
DE (1) DE69726729T2 (pt)
DK (1) DK0904060T3 (pt)
EA (1) EA001219B1 (pt)
EE (1) EE03902B1 (pt)
ES (1) ES2212810T3 (pt)
HK (1) HK1018002A1 (pt)
HR (1) HRP970270B1 (pt)
HU (1) HU227745B1 (pt)
ID (1) ID16926A (pt)
IL (1) IL124935A (pt)
MX (1) MX9805418A (pt)
MY (1) MY123827A (pt)
NO (1) NO320495B1 (pt)
NZ (1) NZ330739A (pt)
PL (1) PL188566B1 (pt)
PT (1) PT904060E (pt)
SI (1) SI0904060T1 (pt)
SK (1) SK284145B6 (pt)
TR (1) TR199801225T2 (pt)
TW (1) TW460282B (pt)
WO (1) WO1997044014A1 (pt)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
PT1039909E (pt) * 1997-12-31 2003-02-28 Choongwae Pharma Corp Metodo de producao e composicao de uma preparacao oral de itraconazole
KR100288890B1 (ko) * 1997-12-31 2001-05-02 최현식 이트라코나졸 경구용 제제 및 그의 제조방법
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
CA2362728C (en) * 1999-03-24 2009-06-23 Fmc Corporation Improved aqueous solubility pharmaceutical formulations
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
ATE329579T1 (de) 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
CA2396380C (en) * 1999-12-23 2015-04-21 David Hayes Improved pharmaceutical compositions for poorly soluble drugs
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
KR100659644B1 (ko) * 2000-06-22 2006-12-21 노파르티스 아게 고형 발사르탄 약제학적 조성물
DE10038571A1 (de) * 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
PT1370543E (pt) 2001-02-14 2007-02-28 Tibotec Pharm Ltd Inibidores de protease de vih 2-(amino-substituída)-benzotiazol-sulfonamida de largo espectro
SK288232B6 (sk) 2001-04-09 2014-11-04 Tibotec Pharmaceuticals Ltd. 2-(substituovaný amino)benzoxazolsulfónamidový derivát, jeho aplikácie ako liečiva, farmaceutická kompozícia s jeho obsahom a spôsob in vitro inhibície retrovírusovej replikácie
DK1387842T3 (da) 2001-05-11 2009-08-10 Tibotec Pharm Ltd Bredspektrede 2-amino-benzoxazolsulfonamid-HIV-protease-inhibitorer
WO2002100407A1 (en) * 2001-06-12 2002-12-19 Smartrix Technologies Inc. Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
ATE444060T1 (de) 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
US7163700B2 (en) * 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
UA79248C2 (en) 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
MXPA04006201A (es) 2001-12-21 2004-12-06 Tibotec Pharm Ltd Sulfonamidas que contienen fenilo sustituido con grupos heterociclicos, inhibidores de la proteasa del vih de amplio espectro.
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
CN1943786A (zh) 2002-02-28 2007-04-11 日本烟草产业株式会社 酯化合物及其医药用途
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
AU2003238074B2 (en) 2002-05-17 2009-04-30 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted benzisoxazole sulfonamide HIV protease inhibitors
US7407670B2 (en) 2002-07-04 2008-08-05 Janssen Pharmaceutica, N.V. Solid dispersions comprising two different polymer matrixes
US7199148B2 (en) 2002-08-14 2007-04-03 Tibotec Pharmaceuticals Ltd Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
DE60312636T3 (de) * 2003-01-14 2014-12-24 Acino Pharma Ag Bioaequivalente Zusammensetzung in der Form einer festen Dispersion enthaltend Itraconazol und ein hydrophiles Polymer
JP4783278B2 (ja) * 2003-02-03 2011-09-28 ノバルティス アーゲー 医薬製剤
EP1648467B1 (en) * 2003-07-17 2018-03-21 Janssen Sciences Ireland UC Process for preparing particles containing an antiviral
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005021486A1 (ja) 2003-08-29 2005-03-10 Japan Tobacco Inc. エステル誘導体及びその医薬用途
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
MXPA06002780A (es) 2003-09-11 2006-06-14 Tibotec Pharm Ltd Inhibidores de entrada del virus de vih.
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
CA2558027A1 (en) * 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AR048650A1 (es) 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
EP2422780A1 (en) 2004-05-07 2012-02-29 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
EP1751165A1 (en) 2004-05-17 2007-02-14 Tibotec Pharmaceuticals Ltd. 4-substituted 1,5-dihydro-pyrido(3,2-b)indol-2-ones
AR049637A1 (es) 2004-05-17 2006-08-23 Tibotec Pharm Ltd 1-fenil-1,5-dihidro-pirido[3,2-b]indol-2-onas sustituidas en las posiciones 6, 7, 8, 9
KR20070015608A (ko) 2004-05-17 2007-02-05 티보텍 파마슈티칼즈 리미티드 1-헤테로사이클일-1,5-디히드로-피리도[3,2-ｂ]인돌-2-온
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
KR20050119397A (ko) * 2004-06-16 2005-12-21 보람제약주식회사 고상용해를 이용한 난용성 약물의 가용화 방법과 이를이용한 가용화 조성물
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
KR100708974B1 (ko) * 2004-07-19 2007-04-18 주식회사종근당 수용성 수지를 이용한 이트라코나졸 고체분산체
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
CA2582767C (en) * 2004-10-25 2011-05-24 Japan Tobacco Inc. Solid formulation with improved solubility and stability and method for producing said formulation
EP1817008B1 (en) 2004-11-09 2020-04-01 Board of Regents, The University of Texas System Stabilized hme composition with small drug particles
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
AR056652A1 (es) 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
PL1912626T3 (pl) * 2005-08-08 2016-10-31 Postaci użytkowe o polepszonej biodostępności
JP5538718B2 (ja) * 2005-08-08 2014-07-02 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつイトラコナゾール組成物
JP5435946B2 (ja) * 2005-08-22 2014-03-05 ジョンズ ホプキンス ユニバーシティ 疾患を処置するためのヘッジホッグ経路アンタゴニスト
US7476405B2 (en) * 2006-02-23 2009-01-13 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
EP2004647A1 (en) 2006-04-03 2008-12-24 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 3,4-dihydro-imidazoý4,5-b¨pyridin-5-ones
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
MX2008016372A (es) 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
US20100003332A1 (en) * 2006-07-27 2010-01-07 Amorepacific Corporation Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
JP2010506833A (ja) * 2006-10-11 2010-03-04 アルファーマ，インコーポレイテッド 医薬組成物
EP2155166A2 (en) * 2007-05-11 2010-02-24 F. Hoffmann-Roche AG Pharmaceutical compositions for poorly soluble drugs
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
WO2009026461A2 (en) * 2007-08-21 2009-02-26 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
EP2471516A3 (en) 2007-09-14 2012-12-26 Wockhardt Limited Rhein or diacerein compositions
EP2520286A1 (en) 2007-09-27 2012-11-07 Wockhardt Limited Pharmaceutical compositions of rhein or diacerein
US20090130160A1 (en) * 2007-11-21 2009-05-21 Fiber Innovation Technology, Inc. Fiber for wound dressing
CA2707161C (en) 2007-11-28 2016-08-16 Sequoia Pharmaceuticals, Inc. Compositions and methods for inhibiting cytochrome p450 2d6
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2009087410A2 (en) * 2008-01-11 2009-07-16 Cipla Limited Solid pharmaceutical dosage form
CA2716348C (en) 2008-02-21 2017-04-04 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome p450
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009236289B2 (en) * 2008-04-15 2014-08-21 Merck Sharp & Dohme Corp. Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and HPMCAS
EA200900145A1 (ru) * 2008-12-31 2010-02-26 Открытое Акционерное Общество "Верофарм" Противогрибковое средство для вагинального применения
CN101780046B (zh) * 2009-01-16 2011-09-21 北京化工大学 一种伊曲康唑复合粉体及其制备方法
ES2453477T3 (es) 2009-12-18 2014-04-07 Frieslandcampina Nederland Holding B.V. Composición de excipiente coprocesada para un comprimido, su preparación y uso
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
ES2511145T3 (es) * 2010-10-14 2014-10-22 Abbott Gmbh & Co. Kg Formulación de dispersión sólida de curcuminoides
CN102068416A (zh) * 2010-12-30 2011-05-25 安徽先求药业有限公司 一种含有伊曲康唑的口服固体制剂及其制备方法
WO2012110469A1 (en) 2011-02-17 2012-08-23 F. Hoffmann-La Roche Ag A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
JP2014521745A (ja) * 2011-08-16 2014-08-28 メルク・シャープ・アンド・ドーム・コーポレーション 安定した非晶質分散体を調製するための無機マトリックスと有機ポリマーの組み合わせの使用
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
AU2012313971B2 (en) 2011-09-27 2016-09-29 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
MX366829B (es) 2012-06-21 2019-07-25 Mayne Pharma Int Pty Ltd Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
JP6235584B2 (ja) * 2012-07-17 2017-11-22 ダウ グローバル テクノロジーズ エルエルシー 高置換ヒドロキシアルキルメチルセルロースを含む固体分散体
WO2014076568A2 (en) 2012-11-19 2014-05-22 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
AU2014210103B2 (en) 2013-01-22 2018-09-06 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
CN105873954B (zh) * 2014-01-16 2019-03-29 陶氏环球技术有限责任公司 用于3d打印的支撑材料
EP3307839B1 (en) * 2015-06-09 2019-02-27 Dow Global Technologies LLC Support materials for 3d printing
WO2017196712A1 (en) * 2016-05-09 2017-11-16 Dispersol Technologies, Llc Improved drug formulations
EP3675832A1 (en) 2017-09-01 2020-07-08 Jordan Sweden Medical and Sterilization Company Fast self dispersible dosage forms of deferasirox
CN109172532A (zh) * 2018-10-24 2019-01-11 北京哈三联科技有限责任公司 一种伊曲康唑分散片及其制备方法和应用
BR112022003812A2 (pt) * 2019-08-28 2022-05-24 Lubrizol Advanced Mat Inc Dispersão sólida amorfa, produto, e, métodos para administrar um ingrediente farmacêutico ativo a uma pessoa ou animal não humano e para formar uma dispersão sólida amorfa de um ingrediente farmacêutico ativo
KR102266145B1 (ko) 2019-09-26 2021-06-17 대봉엘에스 주식회사 비정질 에피나코나졸 고체 분산체
WO2023025672A1 (en) 2021-08-25 2023-03-02 Basf Se Direct tableting auxiliary composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
DE2966564D1 (en) 1978-11-20 1984-02-23 American Home Prod Therapeutic compositions with enhanced bioavailability and process for their preparation
JPS5879915A (ja) * 1981-11-09 1983-05-13 Nippon Soda Co Ltd 棒状薬剤の製造方法
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
JPH0667840B2 (ja) * 1988-11-30 1994-08-31 萬有製薬株式会社 Ｎｂ―８１８の易吸収性製剤
US5028433A (en) 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
PT631578E (pt) * 1992-03-18 2001-11-30 Janssen Pharmaceutica Nv Estereoisomeros de itraconazol e saperconazol
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
JP3413238B2 (ja) 1993-03-31 2003-06-03 オリンパス光学工業株式会社 位相制御膜構造体
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
JP2948111B2 (ja) * 1994-09-16 1999-09-13 塩野義製薬株式会社 経口投与用油性組成物

Also Published As

Publication number Publication date
DE69726729T2 (de) 2004-12-02
SK84898A3 (en) 1999-03-12
SK284145B6 (sk) 2004-10-05
PL188566B1 (pl) 2005-02-28
PT904060E (pt) 2004-04-30
MX9805418A (es) 1998-10-31
BR9706897B1 (pt) 2010-09-21
EE03902B1 (et) 2002-12-16
CZ293841B6 (cs) 2004-08-18
EE9800304A (et) 1999-02-15
AR007195A1 (es) 1999-10-13
IL124935A0 (en) 1999-01-26
CY2434B1 (en) 2004-11-12
US20010007678A1 (en) 2001-07-12
CA2240161A1 (en) 1997-11-27
MY123827A (en) 2006-06-30
TR199801225T2 (xx) 1998-11-23
AU722101B2 (en) 2000-07-20
ATE255883T1 (de) 2003-12-15
AU2956297A (en) 1997-12-09
NZ330739A (en) 1999-06-29
JPH11509238A (ja) 1999-08-17
ID16926A (id) 1997-11-20
US20030082239A1 (en) 2003-05-01
EA199800571A1 (ru) 1998-12-24
EP0904060B1 (en) 2003-12-10
DK0904060T3 (da) 2004-04-13
HRP970270A2 (en) 1998-04-30
EA001219B1 (ru) 2000-12-25
ES2212810T3 (es) 2004-08-01
BG64368B1 (bg) 2004-12-30
HK1018002A1 (en) 1999-12-10
HUP9901620A2 (hu) 1999-10-28
US20060263436A1 (en) 2006-11-23
NO982599L (no) 1998-11-19
WO1997044014A1 (en) 1997-11-27
EP0904060A1 (en) 1999-03-31
US8591948B2 (en) 2013-11-26
CZ188598A3 (cs) 1998-11-11
BG102532A (en) 1999-02-26
US6509038B2 (en) 2003-01-21
HU227745B1 (en) 2012-02-28
US20140134244A1 (en) 2014-05-15
US9642806B2 (en) 2017-05-09
HUP9901620A3 (en) 2000-03-28
CN1209740A (zh) 1999-03-03
CA2240161C (en) 2005-05-24
JP3391801B2 (ja) 2003-03-31
DE69726729D1 (de) 2004-01-22
CN1165291C (zh) 2004-09-08
SI0904060T1 (en) 2004-04-30
US7081255B2 (en) 2006-07-25
TW460282B (en) 2001-10-21
NO320495B1 (no) 2005-12-12
PL330931A1 (en) 1999-06-07
KR19990044257A (ko) 1999-06-25
IL124935A (en) 2001-06-14
NO982599D0 (no) 1998-06-05
HRP970270B1 (en) 2005-02-28

Similar Documents

Publication Publication Date Title
BR9706897A (pt) Composições antifúngicas com biodisponibilidade aperfeiçoada.
HUP0203568A2 (hu) Vírusellenes készítmények
FR2805818B1 (fr) Derives d&#39;azetidine, leur preparation et les compositions pharmaceutiques les contenant
AR098808A2 (es) Una forma de dosificación farmacéutica de fusión instantánea que se desintegrará en la boca en un tiempo de 25 segundos
BG104680A (en) Celecoxib compositions
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
EE200100010A (et) Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
FR2807038B1 (fr) Nouveaux derives d&#39;indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
DE69432559D1 (de) Verwendung von eisenbindenden polymeren zur herstellung eines medikaments zur oralen verabreichung
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
EE200100007A (et) Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis
BR0014383A (pt) Composições de liberação controlada compreendendo nimesulida
HUP0101411A2 (hu) 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása
TR200200981T2 (tr) Farmasötik bileşim terkipleri
EA200400357A1 (ru) Дезинтегрирующиеся в ротовой полости композиции валдекоксиба
DE60116662D1 (de) Hemmung von systemischen infektionen in menschen und wirbeltieren mit ballaststoffen
CA2317465A1 (en) Synthetic polysaccharides, their method of production and pharmaceutical compositions containing same
PT866791E (pt) Diaminopirimidinas formulacoes farmaceuticas que as contem e sua utilizacao antibacteriana
BR0314129A (pt) Formulações de liberação modificadas de oxcarbazepina e derivados destas
HUP0402178A2 (hu) 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény
FR2796380B3 (fr) Nouveaux derives d&#39;aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
MD970244A (en) Dimer lysozime new application

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, POR DESACORDO COM OS ARTIGOS 8O, 13 E 229-A DA LPI, LEI DE NUMERO 9.279 DE 14/05/1996, CUJO REDACAO FORA MODIFICADA PELA LEI 10.196/01, ATRAVES DE PUBLICACAO 9.2 NA RPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/09/2010, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061573/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132265-40.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU:JANSSEN PHARMACEUTICA N.V, JOHNSON AND JOHNSON CONSUMER, NEUTROGENA CORPORATION, KEIKO OTSU LOUIS V. KIRCHHOFF.

B21B Extinction acc. art. 78, item ii - on waiver by the patentee, without prejudice to the rights of third parties

Free format text: SOLICITADA ATRAVES DA PETICAO 860130007859, DE 21/11/2013